The Latest Cardiac and Vascular News
Strengthening discussions with regulatory authorities to accelerate the clinical development of glenzocimab for its potential benefit in the treatment of stroke 87 patients already enrolled in Europe in the ACTISAVE Phase 2/3 registration study in stroke patients ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs […]
End of study brings Robocath closer to commercializing R-One in China in 2023 149 patients enrolled over six months in four Chinese centers Results of first vascular robotics study on this scale in China will be published in March 2023 Rouen, France, July 20, 2022 – Robocath, a company that […]
Company’s cash runway extended into Q3 2023 Ghent, Belgium – 20 July 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces it has entered into a secured loan facility agreement of EUR 10 million […]
Pelacarsen is a potentially first-in-class treatment specifically targeting elevated lipoprotein(a) (Lp(a)), an independent, inherited and causal risk factor for cardiovascular disease There are currently no approved pharmacological therapies to effectively lower Lp(a), which cannot be effectively addressed by diet and other lifestyle changes Topline results expected 2025 CARLSBAD, Calif., July 20, 2022 /PRNewswire/ — Ionis […]
Sales growth of 10.1 percent; organic sales growth of 14.3 percent GAAP diluted EPS growth of 72.7 percent; adjusted diluted EPS growth of 22.2 percent Global COVID-19 testing-related sales of $2.3 billion in the second quarter Continues to strengthen portfolio with new product approvals ABBOTT PARK, Ill., July 20, 2022 /PRNewswire/ — Abbott (NYSE: ABT) […]
HANOVER, Germany–(BUSINESS WIRE)–Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the dosing of the first patient in their multicenter Phase 2 trial assessing efficacy and safety of CDR132L in 280 patients with reduced left ventricular ejection fraction after myocardial infarction […]
Further milestone for company as it fulfills its mission to detect cardiac disease earlier in patients BRISBANE, Calif., July 19, 2022 /PRNewswire/ — Caption Health, the leader in using AI and services to improve heart ultrasound access, today announced that it has received a CE Mark for its Caption AI™ technology platform. This […]
SAN FRANCISCO, July 18, 2022 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced that Dave Vort, the Company’s Chief Commercial Officer, has resigned effective July 25, 2022. To support continued growth and ongoing implementation of iRhythm’s commercial strategy, […]
Company is constructing a new commercial manufacturing facility and anticipates expanding its workforce to support the launch of its comprehensive patient management platform for heart failure LISLE, Ill., July 19, 2022 /PRNewswire/ — Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced plans […]
MARLBOROUGH, Mass., July 19, 2022 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatments for atrial fibrillation (Afib), today announced several milestones toward the development of a next generation pulse field ablation (PFA) technology for treatment of AFib, including the formation of a clinical advisory board, filing of […]
